ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain

Molecular Cancer Therapeutics

Volumn 9, Issue 4, 2010, Pages 929-941

  Yiin, Jia Jean ^a,b,c   Hu, Bo ^a,b   Schornack, Paul A ^b   Sengar, Raghvendra S ^a,b   Liu, Kun Wei ^a,b   Feng, Haizhong ^a,b   Lieberman, Frank S ^a,b   Chiou, Shih Hwa ^a,d   Sarkaria, Jann N ^f   Wiener, Erik C ^a,b   Ma, Hsin I ^e   Cheng, Shi Yuan ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Veteran General Hospital   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^f MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; MUTANT PROTEIN; PROTEIN BCL XL; PROTEIN KINASE B; STAT3 PROTEIN; UNCLASSIFIED DRUG; VANDETANIB;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT;

ANIMALS; BCL-X PROTEIN; BRAIN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; MUTANT PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PIPERIDINES; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STAT3 TRANSCRIPTION FACTOR; TIME FACTORS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77950852399     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0953     Document Type: Article

References (50)

1. Kleihues P, Cavenee WK, editors. Pathology & genetics: tumours of the nervous system. Lyon: IARC Press; 2000.
2. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007;21:2683-2710
3. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359:492-507.
4. Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003;63:6962-6970
5. Nishlkawa R, Ji XD, Harmon RC, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 1994;91:7727-7731
6. Nagane M, Coufal F, Lin H, et al. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 1996;56:5079-5086
7. Rich JN, Bigner DD. Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 2004;3:430-446
8. Huang TT, Sarkaria SM, Cloughesy TF, et al. Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics 2009;6:500-512
9. Hennequin LF, Stokes ES, Thomas AP, et al. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase Inhibitors. J Med Chem 2002;45:1300-1312
10. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:4645-4655
11. Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003;9:1546-1556
12. Rich JN, Sathornsumetee S, Keir ST, et al. ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin Cancer Res 2005;11:8145-8157
13. Wu W, Onn A, Isobe T, et al. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. MolCancer Ther 2007;6:471-483
14. Xiao X, Wu J, Zhu X, et al. Induction of cell cycle arrest and apoptosis In human nasopharyngeal carcinoma cells by ZD6474, an Inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase. Int J Cancer 2007;121:2095-2104
15. Choi S, Sano D, Cheung M, et al. Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 2008;14:5081-5089
16. Yoshikawa D, Ojima H, Kokubu A, et al. Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel moleculartargeted therapy against cholangiocarcinoma. Br J Cancer 2009; 100:1257-1266
17. Heymach JV, Paz-Ares L, De Braud F, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008;26:5407-5415
18. Kovacs MJ, Reece DE, Marcellus D, et al. A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase In patients with relapsed multiple myeloma-NCIC CTG IND.145. Invest New Drugs 2006;24:529-35.
19. Miller KD, Trigo JM, Wheeler C, et al. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, In patients with previously treated metastatic breast cancer. Clin Cancer Res 2005; 11:3369-3376
20. Stupp R, Hegi ME, Gilbert MR, et al. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 2007;25: 4127-4136
21. Natale RB, Bodkin D, Govindan R, et al. Vandetanib versus gefitinib In patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol 2009;27:2523-2529
22. Voelzke WR, Petty WJ, Lesser GJ. Targeting the epidermal growth factor receptor in high-grade astrocytomas. Curr Treat Options Oncol 2008;9:23-31.
23. Sarkaria JN, Yang L, Grogan PT, et al. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther 2007;6:1167-1174
24. Ma HI, Guo P, Li J, et al. Suppression of intracranial human glioma growth after intramuscular administration of an adeno-associated viral vector expressing angiostatin. Cancer Res 2002;62:756-763
25. Huang PH, Mukasa A, Bonavia R, et al. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci U S A 2007; 104:12867-12872
26. Hu B, Shi B, Jarzynka MJ, et al. ADP-ribosylation factor 6 regulates glioma cell invasion through the IQ-domain GTPase-activating protein 1-Rac1-mediated pathway. Cancer Res 2009;69:794-801.
27. Fayed N, Modrego PJ. The contribution of magnetic resonance spectroscopy and echoplanar perfusion-weighted MRI in the Initial assessment of brain tumours. J Neurooncol 2005;72:261-265
28. McConville P, Moody JB, Moffat BA. High-throughput magnetic resonance imaging in mice for phenotyping and therapeutic evaluation. Curr Opin Chem Biol 2005;9:413-420
29. Moffat BA, Hall DE, Stojanovska J, et al. Diffusion imaging for evaluation of tumor therapies in preclinical animal models. Magma 2004;17:249-259
30. Nagane M, Levitzki A, Gazit A, et al. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase3-like proteases. Proc Natl Acad Sci U S A 1998;95:5724-5729
31. Damiano V, Melisi D, Bianco C, et al. Cooperative antitumor effect of multltargeted kinase Inhibitor ZD6474 and ionizing radiation in glioblastoma. Clin Cancer Res 2005;11:5639-5644
32. Sandstrom M, Johansson M, Bergstrom P, et al. Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomlde in an orthotopic glioma model. J Neurooncol 2008;88:1-9.
33. Claes A, Gambarota G, Hamans B, et al. Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenio treatment. Int J Cancer 2008;122:1981-1986
34. Claes A, Wesseling P, Jeuken J, et al. Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Mol Cancer Ther 2008;7:71-78
35. Troiani T, Serkova NJ, Gustafson DL, et al. Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model. Clin Cancer Res 2007;13:6450-6458
36. Williams KJ, Telfer BA, Brave S, et al. ZD6474, a potent Inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin Cancer Res 2004;10:8587-8593
37. Bianco C, Giovannetti E, Ciardiello F, et al. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. Clin Cancer Res 2006;12:7099-7107
38. Ren W, Korenin B, Lahat G, et al. Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma. Clin Cancer Res 2008;14:5466-5475
39. Roberts HC, Roberts TP, Brasch RC, et al. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 2000;21:891-899
40. Hamstra DA, Chenevert TL, Moffat BA, et al. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A 2005; 102:16759-16764
41. Moffat BA, Chenevert TL, Lawrence TS, et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A 2005;102:5524-5529
42. Cha S, Johnson G, Wadghiri YZ, et al. Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with histopathology. Magn Reson Med 2003;49:848-855
43. Vonarbourg A, Sapin A, Lemaire L, et al. Characterization and detection of experimental rat gliomas using magnetic resonance Imaging. Magma 2004;17:133-139
44. McConville P, Hambardzumyan D, Moody JB, et al. Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. Clin Cancer Res 2007;13:2897-2904
45. Moscatello DK, Holgado-Madruga M, Emlet DR, et al. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 1998;273: 200-206
46. Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate antl-apoptotic pathways. Science 2004;305:1163-1167
47. Rahaman SO, Harbor PC, Chemova O, et al. Inhibition of constitutively active Stat3 suppresses proliferation and Induces apoptosis In glioblastoma multiforme cells. Oncogene 2002;21:8404-8413
48. Lo HW, Cao X, Zhu H, et al. Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to lressa and alkylators. Clin Cancer Res 2008;14:6042-6054
49. de la Iglesia N, Konopka G, Puram SV, et al. Identification of a PTENregulated STAT3 brain tumor suppressor pathway. Genes Dev 2008; 22:449-462
50. Huang HS, Nagane M, Klingbeil CK, et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 1997;272:2927-2935